Advice

following a full submission: 

rivaroxaban (Xarelto) is accepted for restricted use within NHSScotland.

Indication under review: Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with:

 - coronary artery disease, or

 - symptomatic peripheral artery disease

 at high risk of ischaemic events.

SMC restriction: use in patients with stable coronary artery disease that does not require dual antiplatelet therapy.

Addition of rivaroxaban to low-dose aspirin (acetylsalicylic acid) reduced the incidence of a composite outcome that included stroke, cardiovascular death and myocardial infarction, mainly due to reductions in stroke and cardiovascular death. It also increased the incidence of major bleeding.

Medicine details

Medicine name:
rivaroxaban (Xarelto)
SMC ID:
SMC2128
Indication:
Co-administered with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events
Pharmaceutical company
Bayer Plc
BNF chapter
Cardiovascular system
Submission type
Full submission
Status
Restricted
Date advice published:
11 February 2019